Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront

For the sec­ond time this year, Sanofi is buy­ing in­to the B cell de­ple­tion work at Dren Bio.

The French phar­ma gi­ant will

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.